191 related articles for article (PubMed ID: 29964125)
1. Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases.
Klug LR; Kent JD; Heinrich MC
Pharmacol Ther; 2018 Nov; 191():123-134. PubMed ID: 29964125
[TBL] [Abstract][Full Text] [Related]
2. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
[TBL] [Abstract][Full Text] [Related]
3. Crenolanib is a selective type I pan-FLT3 inhibitor.
Smith CC; Lasater EA; Lin KC; Wang Q; McCreery MQ; Stewart WK; Damon LE; Perl AE; Jeschke GR; Sugita M; Carroll M; Kogan SC; Kuriyan J; Shah NP
Proc Natl Acad Sci U S A; 2014 Apr; 111(14):5319-24. PubMed ID: 24623852
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Weisberg E; Meng C; Case AE; Sattler M; Tiv HL; Gokhale PC; Buhrlage SJ; Liu X; Yang J; Wang J; Gray N; Stone RM; Adamia S; Dubreuil P; Letard S; Griffin JD
Br J Haematol; 2019 Nov; 187(4):488-501. PubMed ID: 31309543
[TBL] [Abstract][Full Text] [Related]
5. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
6. Avapritinib for metastatic or unresectable gastrointestinal stromal tumors.
Alzofon N; Jimeno A
Drugs Today (Barc); 2020 Sep; 56(9):561-571. PubMed ID: 33025950
[TBL] [Abstract][Full Text] [Related]
7. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.
Galanis A; Ma H; Rajkhowa T; Ramachandran A; Small D; Cortes J; Levis M
Blood; 2014 Jan; 123(1):94-100. PubMed ID: 24227820
[TBL] [Abstract][Full Text] [Related]
8. Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.
Dai J; Kong Y; Si L; Chi Z; Cui C; Sheng X; Mao L; Li S; Lian B; Yang R; Liu S; Xu X; Guo J
Clin Cancer Res; 2013 Dec; 19(24):6935-42. PubMed ID: 24132921
[TBL] [Abstract][Full Text] [Related]
9. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Smith BD; Kaufman MD; Lu WP; Gupta A; Leary CB; Wise SC; Rutkoski TJ; Ahn YM; Al-Ani G; Bulfer SL; Caldwell TM; Chun L; Ensinger CL; Hood MM; McKinley A; Patt WC; Ruiz-Soto R; Su Y; Telikepalli H; Town A; Turner BA; Vogeti L; Vogeti S; Yates K; Janku F; Abdul Razak AR; Rosen O; Heinrich MC; Flynn DL
Cancer Cell; 2019 May; 35(5):738-751.e9. PubMed ID: 31085175
[TBL] [Abstract][Full Text] [Related]
10. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
Apsel Winger B; Cortopassi WA; Garrido Ruiz D; Ding L; Jang K; Leyte-Vidal A; Zhang N; Esteve-Puig R; Jacobson MP; Shah NP
Cancer Res; 2019 Aug; 79(16):4283-4292. PubMed ID: 31270078
[TBL] [Abstract][Full Text] [Related]
11. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Heinrich MC; Griffith D; McKinley A; Patterson J; Presnell A; Ramachandran A; Debiec-Rychter M
Clin Cancer Res; 2012 Aug; 18(16):4375-84. PubMed ID: 22745105
[TBL] [Abstract][Full Text] [Related]
12. A precision therapy against cancers driven by
Evans EK; Gardino AK; Kim JL; Hodous BL; Shutes A; Davis A; Zhu XJ; Schmidt-Kittler O; Wilson D; Wilson K; DiPietro L; Zhang Y; Brooijmans N; LaBranche TP; Wozniak A; Gebreyohannes YK; Schöffski P; Heinrich MC; DeAngelo DJ; Miller S; Wolf B; Kohl N; Guzi T; Lydon N; Boral A; Lengauer C
Sci Transl Med; 2017 Nov; 9(414):. PubMed ID: 29093181
[TBL] [Abstract][Full Text] [Related]
13. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.
Smith CC; Lin K; Stecula A; Sali A; Shah NP
Leukemia; 2015 Dec; 29(12):2390-2. PubMed ID: 26108694
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of PDGFRA and PDGFRB genes by rapid single-strand conformation polymorphism (SSCP) in patients with core-binding factor leukaemias with KIT or FLT3 mutation.
Trojani A; Ripamonti CB; Penco S; Beghini A; Nadali G; Di Bona E; Viola A; Castagnola C; Colapietro P; Grillo G; Pezzetti L; Ravelli E; Patrosso MC; Marocchi A; Cuneo A; Ferrara F; Lazzarino M; Pizzolo G; Cairoli R; Morra E
Anticancer Res; 2008; 28(5A):2745-51. PubMed ID: 19035305
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J; Miettinen M
Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
[TBL] [Abstract][Full Text] [Related]
17. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.
Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM
Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500
[TBL] [Abstract][Full Text] [Related]
18. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract][Full Text] [Related]
19. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
20. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
Indio V; Astolfi A; Tarantino G; Urbini M; Patterson J; Nannini M; Saponara M; Gatto L; Santini D; do Valle IF; Castellani G; Remondini D; Fiorentino M; von Mehren M; Brandi G; Biasco G; Heinrich MC; Pantaleo MA
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
